{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T13:59:55Z","timestamp":1781359195052,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development & Commercialization","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40273-021-01077-8","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T16:44:32Z","timestamp":1633711472000},"page":"121-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["An Integrated Pharmacokinetic\u2013Pharmacodynamic\u2013Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6707-6796","authenticated-orcid":false,"given":"Marjanne A.","family":"Piena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Houwing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1617-5158","authenticated-orcid":false,"given":"Carla W.","family":"Kraan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-3197","authenticated-orcid":false,"given":"Xiaofeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5671-3558","authenticated-orcid":false,"given":"Heidi","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth A.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Mallikaarjun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-5510","authenticated-orcid":false,"given":"Craig","family":"Bennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"1077_CR1","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2020. http:\/\/www.R-project.org\/."},{"key":"1077_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12052","author":"W Wang","year":"2016","unstructured":"Wang W, Hallow KM, James DA. A tutorial on RxODE: simulating differential equation pharmacometric models in R. CPT Pharmacometr Syst Pharmacol. 2016. https:\/\/doi.org\/10.1002\/psp4.12052.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1077_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-3223(01)01303-8","author":"JA Lieberman","year":"2001","unstructured":"Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001. https:\/\/doi.org\/10.1016\/s0006-3223(01)01303-8.","journal-title":"Biol Psychiatry"},{"key":"1077_CR4","unstructured":"National Collaborating Centre for Mental Health. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (Update). Leicester (UK): British Psychological Society. Copyright\u00a9. 2009."},{"key":"1077_CR5","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.499125","author":"O Agid","year":"2010","unstructured":"Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother. 2010. https:\/\/doi.org\/10.1517\/14656566.2010.499125.","journal-title":"Expert Opin Pharmacother"},{"key":"1077_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0507-x","author":"E Biagi","year":"2017","unstructured":"Biagi E, Capuzzi E, Colmegna F, et al. Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly. Adv Ther. 2017. https:\/\/doi.org\/10.1007\/s12325-017-0507-x.","journal-title":"Adv Ther"},{"key":"1077_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.05.028","author":"R Melkote","year":"2018","unstructured":"Melkote R, Singh A, Vermeulen A, et al. Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. Schizophr Res. 2018. https:\/\/doi.org\/10.1016\/j.schres.2018.05.028.","journal-title":"Schizophr Res"},{"key":"1077_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12825","author":"R McCutcheon","year":"2018","unstructured":"McCutcheon R, Beck K, D\u2019Ambrosio E, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand. 2018. https:\/\/doi.org\/10.1111\/acps.12825.","journal-title":"Acta Psychiatr Scand"},{"key":"1077_CR9","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v64n1105","author":"SJ Keith","year":"2003","unstructured":"Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry. 2003. https:\/\/doi.org\/10.4088\/jcp.v64n1105.","journal-title":"J Clin Psychiatry"},{"key":"1077_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2007.07.012","author":"PM Llorca","year":"2008","unstructured":"Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res. 2008. https:\/\/doi.org\/10.1016\/j.psychres.2007.07.012.","journal-title":"Psychiatry Res"},{"key":"1077_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60995-8","author":"J van Os","year":"2009","unstructured":"van Os J, Kapur S. Schizophrenia. Lancet. 2009. https:\/\/doi.org\/10.1016\/S0140-6736(09)60995-8.","journal-title":"Lancet"},{"key":"1077_CR12","unstructured":"Otsuka Pharmaceutical Company. Prescribing information abilify maintena. 2016."},{"key":"1077_CR13","unstructured":"Alkermes. Prescribing information Aristada. 2018."},{"key":"1077_CR14","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S133433","author":"PM Salzman","year":"2017","unstructured":"Salzman PM, Raoufinia A, Legacy S, et al. Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole. Neuropsychiatr Dis Treat. 2017. https:\/\/doi.org\/10.2147\/NDT.S133433.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1077_CR15","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-031120-015212","author":"L Li","year":"2021","unstructured":"Li L, Tran D, Zhu H, et al. Use of model-informed drug development to streamline development of long-acting products: can these successes be translated to long-acting hormonal contraceptives? Annu Rev Pharmacol Toxicol. 2021. https:\/\/doi.org\/10.1146\/annurev-pharmtox-031120-015212.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1077_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2051","author":"D Hill-McManus","year":"2020","unstructured":"Hill-McManus D, Marshall S, Liu J, et al. Linked pharmacometric-pharmacoeconomic modeling and simulation in clinical drug development. Clin Pharmacol Ther. 2020. https:\/\/doi.org\/10.1002\/cpt.2051.","journal-title":"Clin Pharmacol Ther"},{"key":"1077_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00944-0","author":"M Srinivasan","year":"2020","unstructured":"Srinivasan M, White A, Chaturvedula A, et al. Incorporating pharmacometrics into pharmacoeconomic models: applications from drug development. Pharmacoeconomics. 2020. https:\/\/doi.org\/10.1007\/s40273-020-00944-0.","journal-title":"Pharmacoeconomics"},{"key":"1077_CR18","unstructured":"Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review of aripiprazole lauroxil (NDA 207533). 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/207533Orig1s000ClinPharmR.pdf Accessed 15 Jul 2021."},{"key":"1077_CR19","unstructured":"Institute for Cost-Effectiveness Research. ICER\u2019s reference case for economic evaluations: principles and rationale. 2018. https:\/\/icer-review.org\/wp-content\/uploads\/2018\/07\/ICER_Reference_Case_July-2018.pdf Accessed 3 Mar 2021."},{"key":"1077_CR20","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852918001104","author":"HA Nasrallah","year":"2019","unstructured":"Nasrallah HA, Aquila R, Du Y, et al. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS Spectr. 2019. https:\/\/doi.org\/10.1017\/S1092852918001104.","journal-title":"CNS Spectr"},{"key":"1077_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.03.003","author":"SG Potkin","year":"2017","unstructured":"Potkin SG, Risinger R, Du Y, et al. Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation. Schizophr Res. 2017. https:\/\/doi.org\/10.1016\/j.schres.2017.03.003.","journal-title":"Schizophr Res"},{"key":"1077_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0447-7","author":"ML Hard","year":"2017","unstructured":"Hard ML, Mills RJ, Sadler BM, et al. Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model. CNS Drugs. 2017. https:\/\/doi.org\/10.1007\/s40263-017-0447-7.","journal-title":"CNS Drugs"},{"key":"1077_CR23","unstructured":"SAS Institute Inc. Cary, NC, USA. 2021."},{"key":"1077_CR24","unstructured":"Otsuka Pharmaceutical Development and Commercialization Inc. Technical report: exposure-response analyses of impending relapse in pivotal phase 3 safety and efficacy trials of aripiprazole IM depot (Trial 31-07-246 And Trial 31-07-247). 2014."},{"key":"1077_CR25","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S160252","author":"MS Aigbogun","year":"2018","unstructured":"Aigbogun MS, Liu S, Kamat SA, et al. Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. Clinicoecon Outcomes Res. 2018. https:\/\/doi.org\/10.2147\/CEOR.S160252.","journal-title":"Clinicoecon Outcomes Res"},{"key":"1077_CR26","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.841705","author":"MH Lafeuille","year":"2013","unstructured":"Lafeuille MH, Gravel J, Lefebvre P, et al. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ. 2013. https:\/\/doi.org\/10.3111\/13696998.2013.841705.","journal-title":"J Med Econ"},{"key":"1077_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0785-y","author":"T Yan","year":"2018","unstructured":"Yan T, Greene M, Chang E, et al. Medication adherence and discontinuation of aripiprazole once-monthly 400\u00a0mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar i disorder: a real-world study using US claims data. Adv Ther. 2018. https:\/\/doi.org\/10.1007\/s12325-018-0785-y.","journal-title":"Adv Ther"},{"key":"1077_CR28","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.109.067512","author":"S Brown","year":"2010","unstructured":"Brown S, Kim M, Mitchell C, et al. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010. https:\/\/doi.org\/10.1192\/bjp.bp.109.067512.","journal-title":"Br J Psychiatry"},{"key":"1077_CR29","unstructured":"Arias E, Xu JQ, Kochanek KD. United States life tables. 2016. National vital statistics reports. Hyattsville, MD: National Center for Health Statistics; 2019."},{"key":"1077_CR30","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.1737","author":"M Olfson","year":"2015","unstructured":"Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiat. 2015. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.1737.","journal-title":"JAMA Psychiat"},{"key":"1077_CR31","unstructured":"IBM Micromedex. Red Book. 2021."},{"key":"1077_CR32","unstructured":"Centers for Medicaid and Medicare Services. Physician fee schedule. 2021. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched\/index.html Accessed 3 Mar 2021."},{"key":"1077_CR33","unstructured":"Organisation for economic co-operation and development. harmonized consumer price indices by COICOP by country. 2021. https:\/\/stats.oecd.org\/ Accessed 4 Mar 2021."},{"key":"1077_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458348","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012. https:\/\/doi.org\/10.1177\/0272989X12458348.","journal-title":"Med Decis Making"},{"key":"1077_CR35","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.662923","author":"H Ascher-Svanum","year":"2012","unstructured":"Ascher-Svanum H, Furiak NM, Lawson AH, et al. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. J Med Econ. 2012. https:\/\/doi.org\/10.3111\/13696998.2012.662923.","journal-title":"J Med Econ"},{"key":"1077_CR36","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.537594","author":"H Ascher-Svanum","year":"2011","unstructured":"Ascher-Svanum H, Stensland MD, Peng X, et al. Cost-effectiveness of olanzapine vs aripiprazole in the treatment of schizophrenia. Curr Med Res Opin. 2011. https:\/\/doi.org\/10.1185\/03007995.2010.537594.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1077_CR37","first-page":"e55","volume":"19","author":"KJ Smith","year":"2013","unstructured":"Smith KJ, Baik SH, Reynolds CF, et al. Cost-effectiveness of Medicare drug plans in schizophrenia and bipolar disorder. Am J Manag Care. 2013;19(2):e55-63.","journal-title":"Am J Manag Care"},{"key":"1077_CR38","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.917089","author":"L Citrome","year":"2014","unstructured":"Citrome L, Kamat SA, Sapin C, et al. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. J Med Econ. 2014. https:\/\/doi.org\/10.3111\/13696998.2014.917089.","journal-title":"J Med Econ"},{"key":"1077_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-977x(02)80406-0","author":"P Auby","year":"2002","unstructured":"Auby P, Saha A, Ali M, et al. Safety and tolerability of aripiprazole at doses higher than 30 mg. Eur Neuropsychopharmacol. 2002. https:\/\/doi.org\/10.1016\/s0924-977x(02)80406-0.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1077_CR40","unstructured":"US Food & Drug Administration. Model-informed drug development pilot program. 2021. https:\/\/www.fda.gov\/drugs\/development-resources\/model-informed-drug-development-pilot-program."},{"key":"1077_CR41","unstructured":"Otsuka Pharmaceutical Company. Aristada 882 and 1064 dose frequency breakdown (Data on File). 2019."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01077-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01077-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01077-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T02:18:08Z","timestamp":1668133088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01077-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1077"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01077-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"assertion":[{"value":"1 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by a grant from Otsuka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MAP, NH, CB, and CK are employees of OPEN Health and were paid consultants to Otsuka with regard to the development of this manuscript. HW, RAD, XW, and SM are employees of Otsuka. MAP, NH, CB, CK, HW, RAD, XW, and SM have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"Input data for the generation of the results are available in this article and its appendices.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The presented model was built in R version 4.0.2, making use of the RxODE R package. R and RxODE are openly available and licensed under GPL-2\/3. In addition, custom R code was developed by the authors.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors adhered to the International Committee of Medical Journal Editors authorship criteria. MAP was the leading author who designed the pharmacoeconomic model and conducted the analyses together with CK. NH, CB, HW, RAD, XW, and SM contributed to the study design and interpretation of analysis. All authors reviewed the subsequent drafts and provided comments and the final approval of the manuscript for submission.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}